Tarsus PharmaceuticalsTARS
TARS
About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Employees: 323
0
Funds holding %
of 7,202 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
122% more call options, than puts
Call options by funds: $1.39M | Put options by funds: $627K
6% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 33
0% more capital invested
Capital invested by funds: $2.23B [Q4 2024] → $2.23B (+$4.67M) [Q1 2025]
0.81% less ownership
Funds ownership: 105.29% [Q4 2024] → 104.48% (-0.81%) [Q1 2025]
2% less funds holding
Funds holding: 192 [Q4 2024] → 188 (-4) [Q1 2025]
11% less repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 71
22% less funds holding in top 10
Funds holding in top 10: 9 [Q4 2024] → 7 (-2) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$51
13%
upside
Avg. target
$65
45%
upside
High target
$84
87%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Goldman Sachs Andrea Tan | 13%upside $51 | Neutral Maintained | 5 May 2025 |
Guggenheim Eddie Hickman | 87%upside $84 | Buy Maintained | 2 May 2025 |
Jefferies Anthony Petrone | 29%upside $58 | Buy Maintained | 6 Mar 2025 |
HC Wainwright & Co. Oren Livnat | 62%upside $73 | Buy Reiterated | 26 Feb 2025 |
Barclays Balaji Prasad | 33%upside $60 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 10 articles about TARS published over the past 30 days
Negative
Zacks Investment Research
5 days ago
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Tarsus Pharmaceuticals (TARS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Positive
Seeking Alpha
1 week ago
Tarsus Pharmaceuticals: The "Get Big Fast" Approach Could Pay Off
TARS has been marketing Xdemvy (lotilaner) aggressively, with Q1'25 seeing advertisement on network TV, moving beyond previous advertising on streaming platforms. TARS can expand lotilaner beyond Demodex blepharitis, with trials set to initiate in H2'25 in ocular rosacea and 2026 for Lyme disease prevention. TARS is guiding for up to a 25% increase in bottles of Xdemvy dispensed in Q2'25, compared to Q1'25, although the company has often beaten its guidance for bottles dispensed.
Neutral
GlobeNewsWire
1 week ago
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that management plans to participate in the following upcoming investor conferences:
Neutral
PRNewsWire
2 weeks ago
Elanco Sells Royalty and Milestone Rights for Lotilaner in Human Health to Blackstone; Accelerates Debt Paydown
GREENFIELD, Ind. , May 5, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the sale of certain future tiered royalties and commercial milestones associated with XDEMVY® (lotilaner ophthalmic solution) 0.25%, for the human health application of lotilaner, to funds affiliated with Blackstone Life Sciences and Blackstone Credit & Insurance for $295 million in cash.
Neutral
Seeking Alpha
2 weeks ago
Tarsus Pharmaceuticals, Inc. (TARS) Q1 2025 Earnings Call Transcript
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q1 2025 Earnings Conference Call May 1, 2025 4:30 PM ET Company Participants David Nakasone – Head-Investor Relations Bobby Azamian – Chief Executive Officer and Chairman Aziz Mottiwala – Chief Commercial Officer Jeff Farrow – Chief Financial Officer and Chief Strategy Officer Sesha Neervannan – Chief Operating Officer Conference Call Participants Lachlan Hanbury-Brown – William Blair Andrea Newkirk – Goldman Sachs Pavan Patel – Bank of America Eddie Hickman – Guggenheim Cory Jubinville – LifeSci Capital Operator Good day, ladies and gentlemen, and thank you for standing by. Welcome to Tarsus First Quarter 2025 Earnings Conference Call.
Negative
Zacks Investment Research
2 weeks ago
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.64 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $1.01 per share a year ago.
Neutral
GlobeNewsWire
2 weeks ago
Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements
Generated $78.3 million in net product sales of XDEMVY ® , an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients
Positive
Zacks Investment Research
2 weeks ago
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
The mean of analysts' price targets for Tarsus Pharmaceuticals (TARS) points to a 31.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Neutral
GlobeNewsWire
3 weeks ago
Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
IRVINE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Thursday, May 1, 2025, to report its first quarter 2025 financial results and provide a corporate update.
Neutral
GlobeNewsWire
3 weeks ago
Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting
IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the impact of XDEMVY® (lotilaner ophthalmic solution) 0.25% in addressing objective measures of disease at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting, taking place April 25-28, 2025, in Los Angeles, Calif.
Charts implemented using Lightweight Charts™